Amazing stuff! The future of drug development is here! This is only the beginning!
"The makers of an artificial-intelligence system called Virtual Biotech say that it has uncovered a molecular signal that could help to predict clinical-trial success. Virtual Biotech was modelled on a drug company, with up to 37,000 AI agents divided into divisions including target discovery, safety assessment, modality selection and clinical development that interacted with each other and reported to a chief agent ‘scientist’. With some human oversight, Virtual Biotech also identified a potential lung-cancer drug, although human scientists will need to validate the system’s prediction in lab-based studies."
"... The Virtual Biotech comprises as many as 37,000 agents — AI systems that autonomously interact with large language models (LLMs) or with each other and are capable of performing multistep tasks. It uncovered a molecular signal that could help to predict clinical-trial success. And with some human oversight, it identified a promising lung-cancer treatment. ..."
"... The idea ... was to build on the virtual lab, in which AI scientists emulate an academic research laboratory. They created an entire company with tens of thousands of AI agents, all trained to support the full pipeline of drug development. ..."
From the abstract:
"Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development.
We demonstrate its utility at three drug-development decision points.
First, over 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell-type-specific genes were 48% more likely to reach market with 32% fewer adverse events.
First, over 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell-type-specific genes were 48% more likely to reach market with 32% fewer adverse events.
Second, it integrated multimodal evidence to propose a therapeutic strategy in lung cancer.
Third, it analyzed a terminated ulcerative colitis trial and inferred potential mechanisms of failure.
These results demonstrate that human-guided multi-agent systems can conduct transparent, multiscale analyses to inform therapeutic-development decisions."
How a team of AIs discovered a promising lung-cancer drug "Researchers developed a ‘virtual biotech’ made up of as many as 37,000 agents reporting to a ‘chief scientist’."
Virtual biotech company puts thousands of AI scientist agents to work on drug discovery (original news release)
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development (no public access)
The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and Development (preprint, open access)
Fig. 1 Overview of the Virtual Biotech AI agents, tools, and orchestration.
No comments:
Post a Comment